Menu
Recruiting NCT06915116

Acupuncture for People Experiencing Period Loss Due to Chemotherapy

Phase II Interventional Cancer Period Problem

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Acupuncture, No Acupuncture.
Who it may be relevant to
Registry conditions: Cancer, Period Problem. Basic parameters: 15 years — 40 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Acupuncture for Adolescent and Young Adult Cancer Patients: (AcuAYA)

Overview

The purpose of this study is to find out whether it is practical (feasible) to use acupuncture to treat period loss (amenorrhea) caused by chemotherapy treatment in people with cancer. The researchers will look at how many participants enroll and complete the study. The researchers will also study how treatment with acupuncture affects the amount of time for the menstrual cycle to return and symptoms and quality of life related to amenorrhea.

Interventions

  • Procedure Acupuncture
    Acupuncture will be delivered by licensed experienced acupuncturists at MSK. The intervention includes 12 treatments of acupuncture over 12 weeks (i.e. one treatment a week) with a +/- 14-day window. This window applies to the 12-week treatment period rather than to individual visits. The minimum required time between each treatment is 48 hours. When patients experience menses recovery during the treatment period, they have the option to discontinue treatment or continue receiving up to 12 acupu
  • Other No Acupuncture
    Will have the option to receive the same acupuncture treatment as the acupuncture group after a 16-week waiting period

Primary outcome measures

  • Enrollment rate [Time frame: 1 year]
  • Acupuncture treatment adherence rate. [Time frame: up to 16 weeks]
Secondary outcome measures (1)
  • Menses recovery [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • English speaking woman between the ages of 15 and 40
  • History of stage I, II, or III cancer OR stage IV or unstaged hematologic malignancy (e.g. lymphoma, leukemia, myeloma) that is stable, as assessed by care team
  • Premenopausal status with regular menstruation at the time of diagnosis by patient report
  • Completed cytotoxic chemotherapy within the past year
  • Premenopausal status with regular menstruation at the time of diagnosis by patient report for females ages 18 or older
  • Report cessation of menses during or after chemotherapy and have not experienced menses recovery at the time of enrollment.
  • Have reached menarche prior to therapy or during therapy for females between 15 and 17 years old
  • Patient reports cessation of menses during or after chemotherapy and have not experienced menses recovery at the time of enrollment.
  • Have been without menses for at least 3 months 64 following the completion of cytotoxic chemotherapy
  • Willing to adhere to all study-related procedures, including randomization to one of the two possible arms: acupuncture and WLC

Exclusion criteria

  • Had been pregnant or lactating within 3 months prior to enrollment
  • History of hysterectomy or bilateral oophorectomy
  • Ongoing or planned radiation or surgery within 4 months from randomization
  • Use of acupuncture for menses recovery within 3 months of enrollment
  • Had been or will be receiving ovarian suppression medicine, such as leuprolide (Lupron) and goserelin (Zoladex), or hormonal contraception drugs within 3 months of enrollment or during the study period

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 7 centers
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge
  • Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale
  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) — Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) — Rockville Centre

Identifiers

NCT: NCT06915116 · 25-020

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗